Pfizer Inc. and Allergan Plc are considering a merger, the Wall Street Journal reported, setting the stage for a deal that could be among the largest in the drug industry’s history and give Pfizer control of the Botox cosmetic drug.
Pfizer recently approached Allergan and the process is at an early stage, the Journal said, citing people familiar with the matter. Though details of the talks are unclear, they could face obstacles such as agreeing on price, layoffs and closing of facilities, the Journal said.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.